Five hematologic tests and treatments to question

Blood

Volumn 124, Issue 24, 2014, Pages 3524-3528

  Hicks, Lisa K ^a   Bering, Harriet ^b   Carson, Kenneth R ^c   Haynes, Adam E ^d   Kleinerman, Judith ^e   Kukreti, Vishal ^f   Ma, Alice ^g   Mueller, Brigitta U ^h   O'Brien, Sarah H ⁱ   Panepinto, Julie A ^j   Pasquini, Marcelo C ^j   Rajasekhar, Anita ^k   Sarode, Ravi ^l   Wood, William A ^g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d AE Health Consulting   (Canada)

^e Medical Specialists of Taunton   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

ⁱ NATIONWIDE CHILDREN S HOSPITAL   (United States)

^j MEDICAL COLLEGE OF WISCONSIN   (United States)

^k UNIVERSITY OF FLORIDA   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD EXAMINATION; CLINICAL PROTOCOL; EVIDENCE BASED PRACTICE; HEALTH CARE PERSONNEL; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; REVIEW; UNITED STATES; BLOOD; CHRONIC LYMPHATIC LEUKEMIA; DEVICES; FEMALE; HEMATOLOGY; MALE; PROCEDURES; SICKLE CELL ANEMIA; VENOUS THROMBOEMBOLISM;

ANEMIA, SICKLE CELL; FEMALE; HEMATOLOGIC TESTS; HEMATOLOGY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; SOCIETIES, MEDICAL; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84916232429     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-599399     Document Type: Review

References (40)

1. Smith MD; Institute of Medicine (U.S.) Committee on the Learning Health Care System in America. Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. Washington, DC: National Academies Press; 2012.
2. Hicks LK, Bering H, Carson KR, et al. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. Blood. 2013;122(24):3879-3883.
3. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ. 1995;311(7001):376-380.
4. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. [Erratum appears in Chest. 2012;142(6):1698-1704]. Chest. 2012;141(2 suppl):e419S-e94S.
5. Monagle P, Chan AK, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e737S-e801S.
6. Chalmers E, Ganesen V, Liesner R, et al. Guideline on the investigation, management and prevention of venous thrombosis in children. Br J Haematol. 2011;154(2):196-207.
7. Nicolaides A, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism: diagnosis and anticoagulant treatment. Clin Appl Thromb Hemost. 2013;19(2):187-198.
8. National Institute for Health and Care Excellence. Venous Thromboembolic Diseases: The Management of Venous Thromboembolic Diseases and the Role of Thrombophilia Testing. Available from: http://www.nice.org.uk/guidance/CG144/. Accessed June 30, 2014.
9. Scottish Intercollegiate Guidelines Network. Prevention and Management of Venous Thromboembolism (SIGN Publication No. 122). Available from: http://www.sign.ac.uk/guidelines/fulltext/122/index.html. Accessed June 30, 2014.
10. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011;342:d3036.
11. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139(11):893.
12. Hutten BA, Lensing AW, Kraaijenhagen RA, Prins MH. Safety of treatment with oral anticoagulants in the elderly: a systematic review. Drugs Aging. 1999;14:303-312.
13. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e691S-e736S.
14. Eischer L, Eichinger S, Kyrle PA. The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study. J Thromb Haemost. 2014;12(5):635-640.
15. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048.
16. Dutch Institute for Healthcare Improvement. Blood Transfusion Guideline. Available from: http://www.sanquin.nl/repository/documenten/en/prod-en-dienst/287294/blood-transfusion-guideline.pdf. Accessed June 27, 2014.
17. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322(23):1617.
18. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol. 2001;38(1 suppl 1):30.
19. Oscier D, Dearden C, Eren E, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159(5):541-564.
20. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M, Group EGW. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2011;22(suppl 6):vi50-vi54.
21. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219.
22. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198.
23. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910.
24. Brenner DJ, Hall EJ. Computed tomography: an increasing source of radiation exposure. N Engl J Med. 2007;357:2277-2284.
25. Lumbreras B, Donat L, Hernández-Aguado I. Incidental findings in imaging diagnostic tests: a systematic review. Br J Radiol. 2010;83(988):276-289.
26. Mold JW, Stein HF. The cascade effect in the clinical care of patients. N Engl J Med. 1986;314(8):512-514.
27. Deyo RA. Cascade effects of medical technology. Annu Rev Public Health. 2002;23:23-44.
28. Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol. 2012;159(5):528-540.
29. Lo GK, Juhl D, Warkentin TE, Sigouini CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-765.
30. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood. 2012;120:4160-4167.
31. Avila ML, Shah V, Brandão LR. Systematic review on heparin-induced thrombocytopenia in children: a call to action. J Thromb Haemost. 2013;11(4):660-669.
32. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg. 2003;76(6):2121-2131.
33. Patrick AR, Winkelmayer WC, Avorn J, Fischer MA. Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis. Pharmacoeconomics. 2007;25(11):949-961.
34. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207.
35. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am. 1996;25(3):699.
36. Nazi I, Kelton JG, Larché M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946-1953.
37. Grillo-López AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26(5 suppl 14):66.
38. Dong HJ, Ni LA, Sheng GF, Song HL, Xu JZ, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. J Clin Virol. 2013;57(3):209-214.
39. National Institute for Health and Care Excellence. Eltrombopag for Treating Chronic Immune (Idiopathic) Thrombocytopenic Purpura (Review of Technology Appraisal 205). Available from: http://www.nice.org.uk/guidance/ta293. Accessed August 21, 2014.
40. National Institute for Health and Care Excellence. Romiplostim for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura. Available from: http://www.nice.org.uk/guidance/ta221. Accessed August 21, 2014.